Carbomer

Quick links to important sections

Carbomer

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carbomer

Property Description
Active ingredient Polyacrylic acid (functions as an excipient)
Form Incorporated into Gels, Creams, and Ophthalmic Solutions
Pharmacological class Pharmaceutic Aid / Viscosity Increasing Agent
Common use Stabilizing and thickening pharmaceutical formulations
Origin Synthetic Polymer

1. Carbomer: Identity, Origin, and Classification

Carbomer is the generic name for a group of synthetic polymers chemically known as Polyacrylic acid that function exclusively as a pharmaceutic aid or excipient, not as an active medicinal ingredient. This substance is derived from acrylic acid monomers that are chemically cross-linked, which establishes its definitive identity as a man-made compound rather than a natural substance. Carbomers are widely recognized for their use as gelling agents in pharmacy and cosmetics.

As a pharmacologically inactive substance, Carbomer is classified generally as a Viscosity Increasing Agent or a Gelling Agent because its function is strictly limited to altering the physical properties of a medication. Its synthetic origin ensures superior consistency and purity compared to natural thickeners, a critical factor for quality control in formulations regulated for use in topical, ophthalmic, and oral medicines.


2. Chemical Composition and Pharmaceutical Forms

The fundamental composition of Carbomer is the Polyacrylic acid backbone, which exists as a white, hygroscopic powder before formulation. In medication, Carbomer is used as an ingredient in combination with the actual active pharmaceutical ingredients (APIs). Different grades of Carbomer exist (e.g., Carbomer 940), with variations in their molecular weight and degree of cross-linking, resulting in different thickening strengths, an attribute critical for maintaining stability.

Due to its capacity to form a viscous hydrogel matrix when mixed with water and neutralized, Carbomer is essential for creating the structure of various high-level dosage forms, including smooth Gels, stable Creams, and liquid Oral Suspensions, ensuring the even distribution of the medication within the preparation. For example, formulations intended for pediatric patients often utilize Carbomer to create palatable oral suspensions with consistent texture.


3. General Purpose: Why Carbomer is Essential for Medications

The essential purpose of Carbomer is to modify the texture and stability of a medication, functioning as a structural element to achieve proper consistency. Carbomer allows liquids to be converted into semi-solid structures by rapidly forming a stable, internal matrix, which prevents active particles from settling and ensures product stability.

This functional capability makes Carbomer essential for medication performance by allowing it to act as a Stabilizer and, crucially, a bioadhesive polymer. This adhesion ensures that the final product, particularly ophthalmic preparations and skin-applied topical preparations, adheres gently to the target site, increasing the contact time and facilitating the sustained presence of the active drug. Carbomers are utilized to enhance the residence time of eye drops on the surface of the eye.

What side effects are possible with Carbomer?

Possible Side Effects and Safety Information

The safety profile for the excipient Carbomer, used in many drug formulations, is primarily focused on quality control and the presence of manufacturing impurities rather than direct side effects from the polymer itself.

Core Safety Concern: Manufacturing Impurities

Carbomer's official safety concerns center on the presence of benzene, a residual solvent used in the manufacture of certain carbomer grades. Benzene is classified by regulatory bodies as a known human carcinogen (a substance that can cause cancer).

  • Risk: Long-term exposure to high levels of this impurity may potentially lead to serious adverse reactions, including cancers such as leukemia and other blood disorders.
  • Regulatory Action: Due to this risk, government regulatory agencies (such as the FDA) have formally requested the discontinuation of specific carbomer grades (including Carbomer 934, 934P, 940, 941, and 1342) that contain unacceptable levels of residual benzene. Manufacturers are directed to reformulate products using alternative, benzene-free grades.
  • Exposure Limit: Official guidance establishes a strict limit, requiring the impurity benzene to be restricted to no more than 2 parts per million (ppm) in the final drug product to minimize patient exposure.

Other Safety-Related Considerations

  • Contamination Risk: Specific instances of carbomer-containing medical devices (such as certain eye gels) have been subject to safety alerts due to potential microbiological contamination, leading to product recalls to prevent possible infection risks, particularly in severely immunocompromised or critical care patient populations.
  • Quality Standard: The use of carbomer is generally restricted by quality standards that prohibit the excipient if it contains a Class 1 solvent like benzene, establishing the overall safety standard based on the ingredient's source and purity.

Overdose and Emergency Response

Carbomer Overdose and When to Seek Help

The official regulatory profile for Carbomer (Polyacrylic acid), which is classified solely as a pharmaceutically inactive excipient, documents that systemic side effects are not expected to occur even if a quantity greater than the recommended dose is administered. This is consistent with the compound’s minimal systemic absorption. No specific antidote is known or documented in official prescribing information for the polymer itself, and treatment for overexposure is considered supportive.

A critical factor documented by regulatory authorities concerns product quality issues. Official government safety alerts have indicated the risk of microbial contamination in specific batches of Carbomer-containing lubricating eye products, which can lead to severe eye infection and associated complications. This serious risk dictates specific emergency actions.

Emergency Action and Help-Seeking

Regulatory guidance mandates that patients should seek medical attention if any problems perceived as related to an overexposure are noticed. Furthermore, in the event of using an affected product batch, regulators require the user to stop use immediately and contact a healthcare professional urgently if symptoms of eye infection or a worsening condition develop. Population-specific warnings have also been issued for high-risk individuals, such as the severely immunocompromised or those with cystic fibrosis, who were advised to avoid the products during specific contamination incidents.

Therapeutic Uses of Carbomer

What Carbomer Treats: Main Uses and Benefits

Carbomer, a group of polymers primarily made from acrylic acid, is mainly used in pharmaceuticals as an inactive ingredient (excipient) that is considered relevant as an excipient. Its key therapeutic roles are to address symptoms related to localized discomfort and symptoms that interfere with daily functioning in situations where patients experience a need for symptomatic support or a protective layer.

One of its most common direct therapeutic uses is in ophthalmic products (eye drops and gels) where it is commonly used to help with or supports the patient during difficult episodes by easing distress related to dry eye. This is relevant in conditions characterized by periods of heightened symptoms, which often involve the need for supportive lubrication.

Carbomer contributes to easing the overall symptom load. As such, Carbomer is applied in addressing the consistency and stability of various drug formulations, including those used to manage dry eye syndrome, stomatitis, and topical dermatoses where a specialized formulation is useful in scenarios where symptoms escalate temporarily.

“Carbomer may be part of symptomatic management by assisting with the formulation of products like lubricating gels.”

In other medicinal applications, carbomer is applied in addressing the consistency and stability of topical (skin) and oral (ingested) drug formulations. Specific carbomers are also considered relevant in controlled-release or sustained-release tablets and is applied in addressing the need for these specialized formulations, which supports general well-being during symptomatic phases.


Quick Fact: Relief for Ocular Dryness

Regulatory References

  1. MHRA on carbomer-containing lubricating eye gels

Eligibility and Restrictions for Use

Official Eligibility Rules for Carbomer Use

The eligibility for using Carbomer-containing pharmaceutical products, such as ophthalmic gels, is defined by regulatory labels based on patient population, history of allergies, and specific physiological states.

Contraindications and Restrictions

Classification Population or Condition
Absolute Contraindication Individuals with known hypersensitivity or allergy to Carbomer (polyacrylic acid) or to any of the product's excipients (e.g., Benzalkonium chloride).
Conditional Use Restriction Contact lens wearers must remove lenses before application and wait at least 15 minutes before re-insertion due to the presence of preservatives.
Precautionary Use Limitation Pregnant and breastfeeding women: Use is generally not recommended unless the benefit outweighs the risk, as safety has not been formally established.

Permitted Populations and Data Status

Classification Age Group and Data Status
Allowed Populations Adults, including the elderly. Children and adolescents are permitted users.
Data Status Note Safety and efficacy in children and adolescents are supported by clinical experience, though not typically by dedicated clinical trial data for the specific Carbomer grade.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Carbomer’s interaction profile is defined by its function as a pharmacologically inert excipient and its negligible systemic absorption. Consequently, official regulatory documents confirm the absence of traditional systemic interactions, including those mediated by metabolic enzymes or drug transporters. The documented interaction patterns are entirely local and administration-based.

Local Pharmacodynamic Augmentation

A local pharmacodynamic interaction occurs when the Carbomer product is co-administered with other eye drops or eye ointments. The viscosity-increasing property of the polymer is officially documented to prolong the contact-time of the co-administered drug on the ocular surface. Regulatory information indicates that this prolongation may result in an increased local ocular exposure of the other active ingredient.

Mandatory Administration Constraints

This local effect necessitates specific timing-separation rules. When used concurrently with other topical ophthalmic preparations, the Carbomer product must be instilled last and requires an application interval of at least five minutes from the preceding medicine. A separate physical restriction exists concerning soft contact lenses. Due to the potential interaction of the formulation's preservative (such as cetrimide) with the lens material, official regulatory labels require that soft contact lenses be removed prior to application and re-inserted only after an interval of at least fifteen minutes.

Mechanism of Action

How Carbomer Works

Carbomer's function is entirely physicochemical, centered on providing stability to the drug vehicle and regulating the duration of active ingredient exposure at the site of application. It exerts its influence across three primary mechanistic domains:


Physicochemical Rheology Modification

This domain covers the structural change of the compound itself. Carbomer's polyacrylic acid chains undergo rapid hydration and uncoiling upon contact with water and neutralization, resulting in a dense, high-viscosity hydrogel matrix. This structural change imparts stability against particle settling by opposing gravitational forces and maintaining a uniform rheological profile.


Mucoadhesion and Clearance Modulation

The second domain involves Carbomer's physical interaction with biological barriers. The uncoiled polymer chains form hydrogen bonds and ionic interactions with mucin glycoproteins found on mucosal surfaces (like the eye or gastrointestinal lining). This mucoadhesive action mechanically impedes the body's natural physiological clearance pathways, such as tear turnover, prolonging the residence time of the formulation at the intended site.


Control of Drug Release Kinetics

This domain addresses the resulting functional consequence for the accompanying active ingredient. The rigid, viscous hydrogel matrix acts as a physical barrier, making the movement of the dissolved drug dependent on the slow process of diffusion through the polymer network. This physical control over the release mechanism establishes a sustained delivery profile and supports the local availability of the active ingredient.

Dosage and Administration Information

How to Use Carbomer: Official Administration Guidelines

Carbomer is classified as an inactive excipient; consequently, its usage is defined by the official administration instructions for the finished pharmaceutical products it is formulated to stabilize. These instructions govern the route, application schedule, and specific handling requirements for the dosage form.

Administration Scope

The approved pathways for products containing Carbomer are restricted to Topical/Cutaneous application (e.g., creams, gels), Ocular instillation (eye gels and drops), or Oral intake (tablets and suspensions). The application schedule ranges from single daily use (e.g., certain topical treatments) to multiple daily applications (e.g., ophthalmic gels), which is specified on the label of the active drug product.

Feature Official Usage Principle
Standard Dosing Application of a thin film (topical) or one drop (ocular) is the typical non-quantified instruction.
Physical Integrity Oral extended-release tablets must be swallowed whole with water to maintain the controlled-release mechanism provided by the Carbomer matrix.
Handling Restriction Topical forms are explicitly designated FOR EXTERNAL USE ONLY and restricted from ophthalmic use.
Age-Group Rule Ophthalmic products may use the adult recommended posology for children and adolescents.

These official instructions standardize how the medicine is administered, ensuring the product's functional stability and intended physical behavior—particularly the sustained-release profile of oral tablets—are not compromised.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carbomer

The research base for Carbomer was studied for its use as a lubricating agent in eye care, and its role as a formulation aid (excipient) in other medicines. The available evidence, primarily from short-term trials and non-clinical studies, helps contextualize what has been observed so far, as studies help show what has been observed so far in specific settings.


Evidence for Carbomer in Managing Ocular Dryness

Research exploring how symptoms change over time was studied for use in patients with moderate-to-severe dry eye syndrome, which is a condition characterized by fluctuating or episodic manifestations. This evidence comes mainly from short-term Randomized Controlled Trials (RCTs) and comparative studies, where Carbomer was evaluated in contrast to a placebo or another standard lubricant.

Studies reported measurements of change in both patient-reported outcomes describing perceived discomfort and key objective measures like Tear Break-Up Time (TBUT). However, data show patterns related to findings were mixed when examining some other standardized objective measures, such as the Schirmer test score, which did not consistently describe a change across the observed populations. Research highlights changes measured during the study period, but certainty remains low for definitive long-term effects.


Studies on Carbomer's Role in Drug Formulation and Delivery

Carbomer was evaluated in a vast amount of non-clinical and specialized human research for its fundamental role in creating pharmaceutical products. The research base primarily consists of in-vitro (laboratory) and ex-vivo studies that focus on physical properties, such as measuring the strength and gelling characteristics associated with stabilizing active drug ingredients.

Studies report how Carbomer's physical characteristics were observed in relation to the consistency and structure of a medicine. Data show patterns related to measurements of extended contact time for certain active drugs on the surface of the eye or skin in laboratory models, providing context for how Carbomer functions as a structural element in drug delivery systems.

Frequently Asked Questions (FAQ)

Common questions about Carbomer (FAQ)


Q: Is Carbomer the same as other moisturizing eye drops?

A: Carbomer is officially described as a pharmaceutic aid that functions as a tear fluid substitute and lubricant to manage dry eye conditions. Its primary role is to stabilize the formulation and prolong contact time on the eye surface. Regulatory documents confirm this general function, but they do not make direct comparisons between Carbomer and other specific moisturizing drops.


Q: Does Carbomer help with irritated eyes from screen time?

A: Official documents describe Carbomer's use for managing dry eye conditions and unstable tear film. Clinical studies have examined improvements in related symptoms like dry or sandy sensations, which may be experienced following prolonged screen time.


Q: Can Carbomer be used long-term for dry eyes?

A: Official product information suggests a low systemic risk profile for long-term use. This is based on the expectation that systemic exposure to Carbomer is negligible due to its high molecular weight, although studies on long-term efficacy are limited.


Q: Can Carbomer cause blurred vision right after applying it?

A: Yes, temporary blurred vision is a very common side effect reported in official product leaflets and summaries. This sensation usually occurs immediately after application and is temporary, due to the viscosity of the gel. Official guidance indicates waiting until vision is clear before performing tasks that require visual acuity.


Q: Is Carbomer known to interact with common over-the-counter allergy pills?

A: According to official product summaries, no clinically relevant systemic interactions have been described. Carbomer is an excipient with negligible systemic exposure, meaning it is unlikely to interact with oral medications like allergy pills.


Q: Is it normal to have a temporary stinging sensation after using Carbomer?

A: A temporary stinging sensation or eye irritation is listed as a common side effect in official product information. This effect is usually mild and temporary, linked to the gel’s application.


Q: What are the most commonly reported non-serious side effects of Carbomer?

A: The most commonly reported non-serious side effects found in official documentation include eye discomfort, eye irritation, and crusting along the eyelid margin. These effects typically happen locally at the application site.


Q: What does 'opthalmic gel' mean in the context of Carbomer?

A: Ophthalmic gel refers to the pharmaceutical form of the medicine, which is specifically manufactured for application to the eye. Regulatory summaries describe Carbomer ophthalmic products as a clear, colourless liquid gel that acts as a tear substitute.


Q: Are there any food or drink restrictions while using Carbomer?

A: Official information states that there are no known restrictions related to food or drink while using Carbomer. This is because the regulatory expectation is for the drug to have negligible systemic exposure.


Q: What is the purpose of the inactive ingredients in Carbomer products?

A: Besides Carbomer, inactive ingredients in the product typically include a preservative (like cetrimide), water for injection, and compounds such as sorbitol and sodium hydroxide. These components function as buffers and stabilizers to maintain the gel's consistency and pH.


Q: Is the sensation of stickiness after using Carbomer normal?

A: The sensation of stickiness or grittiness is a commonly reported discomfort. This is considered normal and is related to the viscous, gel-like consistency of the formulation on the eye surface.


Q: Can Carbomer be used alongside artificial tears?

A: Yes, Carbomer products can be used alongside other eye drops, including artificial tears. Official guidelines specify that the Carbomer product is typically instilled last, requiring an interval of at least five minutes after the previous application.


Q: Is there a link between Carbomer and eye irritation worsening?

A: Eye irritation is listed as a common side effect of Carbomer products. Official safety information advises that if irritation, pain, or redness persists or worsens, discontinuation of use is indicated.


Q: Does Carbomer contain preservatives, and is that a concern?

A: Some Carbomer products contain preservatives, such as cetrimide, which may cause eye irritation in some individuals. The regulatory documentation notes that this preservative can also discolour soft contact lenses, which is why removal is required before use.


Q: What research is available about Carbomer use in pregnancy?

A: Official product information states that there are no available data from the use of Carbomer in pregnant women. However, due to the drug's high molecular weight, effects on the unborn child are not anticipated as systemic exposure is expected to be negligible.


Q: How long does the moisturizing effect of one Carbomer application last?

A: Studies cited in official product summaries indicate that the application of Carbomer gel can maintain tear film stability for a period of up to six hours. This duration is thought to be supported by the gel's mucoadhesive properties.


Q: Does Carbomer interact with supplements like fish oil or multivitamins?

A: Official product information reports that no clinically relevant systemic interactions have been described. As Carbomer is an excipient with negligible systemic absorption, it is not known to interact with oral supplements.


Q: Why do official documents emphasize washing hands before using Carbomer?

A: Official administration instructions emphasize strict hygiene to avoid contamination of the product. Handwashing helps minimize the risk of transferring germs or dirt to the container tip, which must not touch any surface.


Q: What happens if Carbomer is accidentally used in the nose or mouth?

A: Official labeling specifies that the product is for ocular use only. If the product is accidentally swallowed, official instructions specify that contact with a Poison Control Center is indicated.


Q: Is there any research on long-term safety beyond a few years of Carbomer use?

A: Research on the excipient focuses on its physical properties. Official information suggests that due to Carbomer's high molecular weight and negligible systemic absorption, absorption or accumulation in eye tissues is considered unlikely by official sources.


Q: Why does the packaging mention checking the tip of the dropper?

A: Packaging instructions emphasize checking the tip of the container to prevent contamination or accidental injury to the eye. Official guidance states that the tip of the container must not touch the eye or any other surface to help maintain sterility.


Q: Are there reported cases of severe side effects from Carbomer?

A: Official post-marketing experience includes reports of severe adverse reactions such as allergic reactions. Official warnings indicate that seeking medical attention is required if severe eye pain, persistent redness, or vision changes occur.


Q: What should I know about using Carbomer before driving?

A: Carbomer may temporarily affect visual acuity by causing blurred vision immediately after application. Official guidance indicates waiting until vision has cleared completely before driving or operating any machinery.


Q: Is it true that Carbomer is generally only for moderate to severe dryness?

A: Regulatory documents indicate that Carbomer is generally indicated as a tear fluid substitute for the management of dry eye conditions and unstable tear film. This general indication does not officially restrict its use only to moderate-to-severe cases.


Q: Can Carbomer make eyes feel gritty or sandy?

A: The sensation of grittiness or sandiness in the eye is a subjective symptom often associated with the dry eye condition that Carbomer treats. Clinical studies indicate an improvement in this symptom following Carbomer use.


Q: What are the common signs that Carbomer is working as intended?

A: Official information and clinical studies describe Carbomer as improving tear film stability and relieving subjective symptoms. Common signs that the product is working include a decrease in feelings of dryness, discomfort, and foreign body sensation.


Q: How does Carbomer affect tear film stability?

A: Studies cited in official documentation confirm that Carbomer improves tear film stability and prolongs the Tear Break-Up Time (BUT). This effect is thought to be supported by the formation of a lubricating, mucoadhesive film on the eye surface.


Q: Does Carbomer contain any substances derived from animals?

A: No, official information confirms that Carbomer is a synthetic excipient. It is chemically defined as a high molecular weight, crosslinked polymer derived from acrylic acid monomers, meaning it does not contain substances derived from animals.


Q: Can Carbomer be used by people with glaucoma?

A: Use of Carbomer products is permitted for people receiving glaucoma therapy. Official interaction rules specify that if other local ocular treatment is being used, the Carbomer product is to be applied last, with a 5-minute interval between products.

How should Carbomer be stored and disposed of?

How to Store and Dispose of Carbomer?

Official regulatory guidelines for Carbomer-containing medicinal products (such as ophthalmic gels) define strict storage and disposal requirements to ensure product integrity and safety.

Storage & Stability Requirement Official Statement
Temperature and Freezing Do not store above 25 C or 30 C (depending on the product). Do not freeze.
Container Integrity Keep the medicine in its original packaging and ensure the container is recapped tightly after each use.
Shelf-Life After Opening Multi-dose containers must be discarded 28 days after first opening.
Child Protection Keep out of the sight and reach of children.

Disposal instructions from official labels prohibit discarding this medicine via wastewater or household waste. Unused or expired Carbomer products must be taken to a pharmacist or an authorized collection point for proper destruction, following local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Carbomer found in:

A-Z Index: